“US Food and Drug Administration”: 6 people who received the Pfizer Corona vaccine died (details)

A report from the US Food and Drug Administration said that 6 people during the Corona vaccine experiments developed by the American pharmaceutical company “Pfizer” and the German company “Biontech”: “One of the participants in the tests from the vaccine developed obesity and hardening of the arteries, and died 3 days after taking the first dose of the drug, “explaining that” the second deceased volunteer suffered a heart attack 60 days after the second dose, “according to the American website. Politician.

The report also noted that “among the participants who received the vaccine, two died as a result of a heart attack and a stroke, while the cause of death of two other people is being determined.”

He noted that “of the six deceased, 3 are over 55 years old.”

According to the US website “CBC”, the US Food and Drug Administration will hold a “scientific tribunal” on Thursday that will discuss, publicly and disseminate, the robustness of the data supporting vaccines. This public examination is seen as key to building confidence ahead of what is expected to be the largest vaccination campaign in state history. United.

A panel of independent scientists will choose an initial FDA review before recommending whether a vaccine appears safe and effective enough for millions of Americans.

The Food and Drug Administration, which generally follows the advice of the committee, is expected to issue a decision in the days following the review. If given the green light, the first beneficiaries will be health workers and residents of nursing homes according to the plans established by each state.

Reviewers from the Food and Drug Administration agreed that the vaccines were very protective. The agency confirmed that they have also worked on the elderly, which is of particular concern.

It is reported that among volunteers over 55 years of age, there were three cases of Coronavirus infection, who were vaccinated and 48 cases were among those who received placebo treatment, and 5 of the cases were among people aged 75 years and over, all which received a placebo injection.

Agency staff noted that more data will be needed to assess the potential of a single dose.

She said the efficacy after the first dose and before the second dose was about 52%.